Marker Therapeutics provides update on MT-601 patients

Marker Therapeutics (MRKR) provided an update on the progress and clinical observations from the Phase 1 APOLLO study, with a data cutoff date of September 10. Key findings from the APOLLO study include: Infusion of MT-601 was well tolerated in all study participants, with no observation of immune-effector cell associated neurotoxicity syndrome and one reported Grade 1 cytokine release syndrome. No dose limiting toxicities have been reported to date. In the first dose cohort, 7 out of 9 patients achieved objective responses at first response assessment, with 4 patients demonstrating complete response. Long-term follow-up of 6 to 12 months is currently available for three patients Ongoing follow-up visits are being conducted to assess the durability of responses. All study participants are monitored closely to ensure comprehensive data collection and patient safety.